ArticleOncotarget2015

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Jason S Kirk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.